Should preclinical studies be registered?

Download
  1. (PDF, 36 KB)
DOIResolve DOI: http://doi.org/10.1038/nbt.2261
AuthorSearch for: ; Search for:
TypeArticle
PubMed Central IDPMC4516408
Funding Reference Number102823-1
PubMed ID22678379
CAMS IDcams4748
Copyright noticeSee terms of use in CIHR Copyright and Disclaimer Notices.
Journal titleNature biotechnology
ISSN1087-0156
1546-1696
Volume30
Issue6
Pages488489
Publication date
References
  1. Clinical trial registration: looking back and moving ahead
  2. Shining a light on trial data
  3. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy
  4. Can the pharmaceutical industry reduce attrition rates?
  5. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis
  6. Neutralization of tumor necrosis factor in preclinical models of sepsis
  7. Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?
  8. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
  9. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis
  10. Issues in the registration of clinical trials
Export citationExport as RIS
CollectionCanadian Institutes of Health Research 2009–2017
Record identifier1072dc29-2173-4e14-acfe-faf2191aa57b
Record created2018-04-26
Record modified2018-04-26
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
Date modified: